SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The ticket is $Testicle. EVERY SINGLE ONE OF YOU CAME FROM A $Testicle. $Testicle always bounce.   We have a website on which you can create art or memes. We have a community. We have a raid group. We aim to provide the best testicular care on CT.   We might even have to call on our nefarious leader, Harry Bolz. Alright Chad, SACK TF. Or else you’re a Low T beta male.   If you have questions and or concerns please feel to reach out to a team member on how you can acquire or become a high testosterone male in a sea of betas. I mean how else does one live if not as a High T male?

Testicle

TESTICLE CRYPTO is trending due to its outrageous name and perceived meme coin status, sparking a divided but highly engaged community discussion. Investors are either "all-in" for what they jokingly or seriously call a "generational hold," or outright dismissing it as a joke and a symptom of a "broken" market. The token's notoriety is amplified by its association with similarly named cryptocurrencies like $BALLSACK, fueling conversations around speculative investments in the current market environment.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical (DRTS) is trending due to overwhelming community excitement following perceived success at the J.P. Morgan Healthcare Conference and high anticipation for imminent PMDA approval in Japan. Investors are rallying around the company's Alpha DaRT technology, citing impressive clinical data in pancreatic cancer and glioblastoma, which is fueling belief in a revolutionary approach to oncology and attracting significant institutional interest, including rumored accumulation by Cathie Wood.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Arrowhead Pharmaceuticals Inc.

Arrowhead Pharmaceuticals is trending following the landmark FDA approval of REDEMPLO (plozasiran) for familial chylomicronemia syndrome, a pivotal milestone that establishes the company as a commercial-stage entity. This achievement is sparking strong community enthusiasm, with discussions highlighting REDEMPLO's market-leading potential and its role in de-risking a deep RNAi pipeline that includes highly anticipated obesity drug data and a groundbreaking CNS delivery platform. Many investors feel the market has yet to fully appreciate these platform capabilities, suggesting the stock remains significantly undervalued despite recent analyst price target adjustments.

Groupon, Inc. engages in the global scaled two-sided marketplace that connects consumers to merchants. It operates through the North America and International geographical segments. The company was founded by Andrew D. Mason, Eric Paul Lefkofsky, and Bradley A. Keywell in October 2008 and is headquartered in Chicago, IL.

Groupon Inc

Groupon is experiencing significant market attention, primarily driven by strong community speculation about a potential short squeeze, given its notably high short interest and institutional accumulation, particularly by Pale Fire Capital. Bulls highlight strategic business developments, including a recent health deal and the hidden value of its SumUp stake, as signs of a turnaround. However, many skeptics fiercely debate its fundamental valuation, attributing recent price movements to manipulation rather than sustained growth.

Venture Global, Inc. engages in the development and construction of liquefied natural gas production, establishing us as a rapidly growing company delivering critical LNG to the world. It projects include Calcasieu, Plaquemines, CP2, CP3 and Delta projects. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is trending as its Plaquemines LNG facility demonstrates increasing operational efficiency through rising cargo exports and approved capacity expansion without new capital expenditure. The community is actively discussing favorable natural gas price spreads and high short interest, alongside ongoing anticipation for resolutions in its legal disputes.

Babcock & Wilcox Enterprises, Inc. engages in the provision of fossil and renewable power generation and environmental equipment. It operates through the following segments: B&W Renewable, B&W Environmental, and B&W Thermal. The B&W Renewable segment supports a circular economy, diverting waste from landfills to use for power generation and replacing fossil fuels, while recovering metals and reducing emissions. The B&W Environmental segment focuses on systems for cooling, ash handling, particulate control, nitrogen oxides and sulfur dioxides removal, chemical looping for carbon control, and mercury control. The B&W Thermal segment offers steam generation equipment, aftermarket parts, construction, maintenance, and field services for plants in the power generation, oil and gas, and industrial sectors. The company was founded by George H. Babcock, Stephen Wilcox, Jr., and Joseph P. Manton in 1856 and is headquartered in Akron, OH.

Babcock & Wilcox Enterprises Inc

Babcock & Wilcox (BW) is attracting significant attention as investors anticipate the imminent finalization of a transformative $1.5 billion contract with Applied Digital (APLD). This pivotal deal, centered on providing 1 GW of natural gas power for a new AI data center, is widely viewed by the community as a game-changer, establishing BW as a crucial and rapidly deployable energy solution for the booming AI infrastructure.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending high following significant regulatory approval for its ANKTIVA therapy in Saudi Arabia for both bladder and lung cancers, which is seen by many as a pivotal de-risking event. This catalyst, coupled with robust preliminary revenue growth and the CEO's active engagement, is sparking widespread community discussions about a potential short squeeze and a transformative shift in cancer treatment paradigms.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. It focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPMorgan Chase is trending due to a high-profile lawsuit threat from Donald Trump and his proposal to cap credit card interest rates, sparking intense debate about regulatory impacts on the financial sector. This political pressure compounds mixed reactions to JPM's recent quarterly earnings, where a stock dip occurred despite a beat, largely attributed to an Apple Card reserve, prompting community discussions on market resilience and potential banking profitability shifts.

Centene Corp. is a healthcare enterprise, which engages in the provision of programs and services to government sponsored healthcare programs. It operates through the following segments: Medicaid, Medicare, Commercial, and Other. The Medicaid segment includes the Temporary Assistance for Needy Families program, Medicaid Expansion programs, the Aged, Blind or Disabled program, the Children's Health Insurance Program, Long-Term Services and Supports, Foster Care, Medicare-Medicaid Plans, which cover beneficiaries who are dually eligible for Medicaid and Medicare, and other state-based programs. The Medicare segment consists of Medicare Advantage, Medicare Supplement, Dual Eligible Special Needs Plans, and Medicare Prescription Drug Plans. The Commercial segment is involved in the Health Insurance Marketplace product along with individual, small group, and large group commercial health insurance products. The Other segment refers to pharmacy operations, Envolve Benefit Options’ vision and dental services, clinical healthcare, behavioral health, the TRICARE program, and corporate management companies. The company was founded in 1984 and is headquartered in St. Louis, MO.

Centene Corp.

Centene Corp (CNC) is trending amid heated debate over the potential extension of Affordable Care Act (ACA) subsidies and proposals by former President Trump to redirect healthcare funding directly to individuals. The community is divided, with some anticipating an extension to be bullish for managed care, while others fear significant policy changes could negatively impact insurers heavily exposed to government programs. This uncertainty is driving discussions around institutional accumulation versus retail selling, as the sector grapples with evolving political narratives.

Direxion Shares ETF Trust - Direxion Daily TSLA Bull 2X Shares

Direxion Daily TSLA Bull 2X Shares

TSLL is trending due to significant volatility, recently impacted by a notable dividend distribution that caused a sharp price drop and options market disruption, fueling intense debate among traders. The community is sharply divided, with many buying the dip on its underlying asset, TSLA, driven by optimism around AI and robotics, while others remain bearish, citing valuation concerns and the leveraged ETF's inherent decay.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Magnite Inc. (MGNI) attracted strong retail chatter on Stocktwits on Monday as the shares of the omni-channel sell-side advertising platform provider jumped during the session.In Tuesday's early premarket session, the stock gave some of the gains as it traded down by over 0.50%.The New York-based company benefited from a positive analyst action, which sent its shares soaring by 14.31% on Monday, with the upside accompanied by more than twice the average volume.According to Investing.com, Rosenblatt Securities maintained a ‘Buy’ rating for&nbsp;<a href="https://stocktwits.com/symbol/MGNI">Magnite stock</a> and raised the price target to $39 from $18 on Monday.&nbsp;Analysts at the research firm expect the company to reap substantial benefits from the upcoming AdTech antitrust remedy and penalty phase against Alphabet, Inc.’s (GOOGL) (GOOG) Google.&nbsp;In late April, a judge ruled that Google violated U.S. antitrust laws by monopolizing the markets for publisher ad servers and ad exchanges, and by illegally tying its ad server to its ad exchange.The benefits that Rosenblatt estimates could accrue as early as 2026, the analysts said, adding that it sees earnings improvement from behavioral remedies and potential proceeds from settlements.&nbsp;Rosenblatt said the stock price hasn’t yet baked in the potential benefits.Additionally, analysts believe that the ruling against Google was strong, potentially withstanding appeals, if any, thereby creating a favorable environment for Magnite in the digital advertising ecosystem.Following Rosenblatt’s note, the message volume on the Magnite stream on Stocktwits increased by 6,800% over the 24 hours leading up to late Monday.&nbsp;Sentiment toward the stock remained ‘extremely bullish’ (79/100) by early Tuesday.<figure class="image"><img style="aspect-ratio:617/50;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_01_at_5_10_00_AM_png_03fb91a309.webp" alt="Screenshot 2025-07-01 at 5.10.00 AM.png" width="617" height="50"><figcaption>MGNI sentiment and message volume as of 5:10 a.m. ET, July 1 | source: Stocktwits</figcaption></figure>Magnite stock has gained over 51% this year, and it hit a multi-year high of $24.46 in Monday’s session.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-says-musk-would-head-back-home-to-south-africa-without-subsidies/chFW3YqRRrE">Trump Says Musk Would 'Head Back Home To South Africa' Without Subsidies — Tesla CEO Dares President To 'Cut It All'</a>

The Magnite logo is seen displayed on a smartphone screen.

Magnite Retail Chatter Spikes After Stock Hits Multi-Year Highs As Analyst Flags ‘Substantial’ Benefits From Google Adtech Antitrust Ruling

The benefits that Rosenblatt estimates could accrue as early as 2026, the analysts said, adding that it sees earnings improvement from behavioral remedies and potential proceeds from settlements. 

Equity

The benefits that Rosenblatt estimates could accrue as early as 2026, the analysts said, adding that it sees earnings improvement from behavioral remedies and potential proceeds from settlements. 


Atlassian Corp. (TEAM) stock has gained nearly 18% since the collaboration software services and tools provider reported a beat-and-raise quarter. An analyst said Friday he is “incrementally positive” on the stock but opted to stay on the sidelines.Macquarie analyst Steve Koenig upped his price target for <a href="https://stocktwits.com/symbol/TEAM">Atlassian stock</a> as the stellar fiscal year second-quarter performance prompted him to revise his estimates for the company upwardly.&nbsp;The analyst attributed the second-quarter beat to the conservative guidance approach, which accommodates macro and execution risks. He also noted that the company stuck with its conservative approach in its fiscal year 2025 guidance as new Chief Revenue Officer Brian Duffy took over the sales team.&nbsp;Koenig expects Atlassian to maintain its 2025 momentum, citing the stability in the quarterly revenue trends and the 15%-25% data center price increases on contracts renewing after Feb. 11.The analyst said, “We're incrementally more positive on the potential for continued momentum to set the company up for near-term outperformance and easier FY27 comparisons that don't require acceleration.He is also encouraged by the company’s ability to derive more value per seat, which will likely offset macro headwinds.That said, Koenig believes that the multiple now looks stretched. "We could become more constructive if we gain visibility into FY26 (upside) and/or a more attractive entry point for TEAM shares," he added.&nbsp;The updated price target of $317 suggests a less than 1% upside from current levels.Macquarie has a ‘Neutral’ rating on Atlassian stock.<figure class="image"><img style="aspect-ratio:632/138;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/team_sentiment_8b2dea7843.png" alt="team-sentiment.png" width="632" height="138"><figcaption>TEAM sentiment and message volume February 10, as of 2:17 am ET | Source:&nbsp;Stocktwits</figcaption></figure>On Stocktwits, retail sentiment toward Atlassian stock turned ‘extremely bullish’ from merely ‘bullish’&nbsp; a day ago. The message volume remained at ‘normal’ levels.Atlassian stock ended Friday’s session down 1.48% at $314.28. The stock has gained over 29% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/roblox-under-active-sec-investigation-report-says-retail-braces-for-further-stock-decline/ch53xNzRtX">Roblox Under Active SEC Investigation, Report Says: Retail Braces For Further Stock Decline</a>

The Jira Cloud by Atlassian app page is displayed on a smartphone in the Apple App Store in front of the Atlassian Corporation logo on October 31, 2024 in Chongqing, China. 

Atlassian Analyst ‘Incrementally Positive’ On Stock Yet Remains On Sidelines: Retail Turns Increasingly Bullish

 Analyst Steve Koenig expects Atlassian to maintain its 2025 momentum, citing the stability in the quarterly revenue trends and the proposed 15%-25% data center price increases.

Current Price	$40.84
Prev Close	$40.93
Open	$41.19
Dividend Yield	N/A
50-Day Moving Average	$40.72
Beta	N/A
Avg. Volume	11,969.45
PE Ratio	N/A

52-Week High	$43.80
52-Week Low	$26.71
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

FDTX
Fidelity Disruptive Technology ETF

Feed

News

Sentiment

Fundamentals

Info

Latest FDTX News

FDTXFidelity Disruptive Technology ETF